Keros Therapeutics KROS
NASDAQ KROS
$11.35 +0.17 (+1.52%)
At close: Oct 22, 2026 · 4:00 PM EDT

Keros Therapeutics (KROS) Price to Earnings (2025)

Updated

Keros Therapeutics' Price to Earnings was 8.71 in Q4 2025, down 12.7% from the prior quarter.

Analysis

Keros Therapeutics (KROS) Price to Earnings (2025) Analysis & Trends

From Q1 2025 onward, Keros Therapeutics has reported Price to Earnings for 4 quarters.

  • Per Business Quant data, KROS's Price to Earnings in the three quarters before Q4 2025 was 9.97 (Q3 2025), 28.88 (Q2 2025) and 98.13 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn
10 Keros Therapeutics 221.17 Mn -1.71 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 8.71
Sep 30, 2025 9.97
Jun 30, 2025 28.88
Mar 31, 2025 98.13
API Access

Keros Therapeutics Price to Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-earnings&ticker=KROS&period=max&api_key=YOUR_API_KEY